Icon
+91 94997 68112
Login Register

VONJO - (EQ 100MG BASE ; Capsule)

PACRITINIB CITRATE Sobi
EQ 100MG BASE ; Capsule
Less Than $1000 mn
None None
Less Than 5
 None
None None
VONJO is a kinase inhibitor indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.
Yes
VONJO Patent 1 Patent 2 Patent 3
*** *********
****** ****** ********** *********** ****** ****** ********** *********** **-(*-**********-*-**-******)-**,**-*****-*,*,**-******-**********[**.*.*.*(*,*).*(*,**)]*********-*(**),*(**),*,*,*,**,**(**),**,**,**-******* ******* ****
  1. *** **, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. *,***,*** (******* **, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** ******* **, ****.
  2. *** **, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. *,***,*** (*** *, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** *** **, ****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.